



20<sup>th</sup> February, 2025

The Secretary,  
Bombay Stock Exchange Limited  
Phiroze Jeejeebhoy Towers  
Dalal Street,  
Mumbai – 400 001  
Scrip Code: 544250

The Secretary,  
The National Stock Exchange of India Limited  
C-1, Block G, Exchange Plaza  
Bandra-Kurla Complex  
Bandra East, Mumbai - 400 050  
Symbol: SANOFICONR

**Sub.: Integrated Filing (Financials) for the quarter and financial year ended December 31, 2024**

Dear Sir/ Madam,

Pursuant to SEBI Circular No. SEBI/HO/CFD/CFD-PoD2/CIR/P/2024/185 dated December 31, 2024, read with BSE Circular No. 20250102-4 and NSE Circular No. NSE/CML/2025/02 dated January 02, 2025, we are submitting herewith the Integrated Filing (Financials) for the quarter and financial year ended December 31, 2024.

Kindly take the same on your record.

Thanking you,

Yours faithfully,

For **Sanofi Consumer Healthcare India Limited**

---

**Nikunj Kumar Savaliya**  
**Company Secretary and Compliance Officer**  
**Membership No.: FCS 7048**



A. Financial Results: **Annexure A**

B. Statement on deviation or variation for proceeds of public issue, rights issue, preferential issue, qualified institutions placement etc.: **Not Applicable**

C. Format for disclosing outstanding default on loans and debt securities: **Not applicable, as there were no default in the quarter ended December 31, 2024**

D. Format for disclosure of related party transactions (applicable only for half-yearly filings i.e., 2nd and 4<sup>th</sup> quarter): **Annexure B**

E. Statement on impact of audit qualifications (for audit report with modified opinion) submitted along-with annual audited financial results (Standalone) (applicable only for Annual Filing i.e., 4<sup>th</sup> quarter): **Not Applicable**

# KALYANIWALLA & MISTRY LLP

CHARTERED ACCOUNTANTS

---

## INDEPENDENT AUDITOR'S REPORT

### TO THE BOARD OF DIRECTORS OF SANOFI CONSUMER HEALTHCARE INDIA LIMITED

#### Report on the Audit of the Financial Results

#### Opinion

We have audited the accompanying Annual Financial Results of **Sanofi Consumer Healthcare India Limited** (“the Company”) for the year ended December 31, 2024, attached herewith, being submitted by the Company pursuant to the requirement of Regulation 33 of the Securities and Exchange Board of India (“SEBI”) (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended (“LODR Regulations”).

In our opinion and to the best of our information and according to the explanations given to us, these financial results:

- i. are presented in accordance with the requirements of Regulation 33 of the LODR Regulations in this regard; and
- ii. gives a true and fair view in conformity with the applicable accounting standards (“Ind AS”) and other accounting principles generally accepted in India, of the net profit and other comprehensive income and other financial information for the year ended December 31, 2024.

#### Basis for Opinion

We conducted our audit in accordance with the Standards on Auditing (“SAs”) specified under section 143(10) of the Companies Act, 2013 (“the Act”). Our responsibilities under those Standards are further described in the *Auditor’s Responsibilities for the Audit of the Financial Results* section of our report. We are independent of the Company, in accordance with the Code of Ethics issued by the Institute of Chartered Accountants of India (“the ICAI”) together with the ethical requirements that are relevant to our audit of the financial results under the provisions of the Act and the Rules thereunder, and we have fulfilled our other ethical responsibilities in accordance with these requirements and the Code of Ethics. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.

#### Board of Director’s Responsibilities for the Financial Results

These financial results have been prepared on the basis of the annual financial statements. The Company’s Board of Directors are responsible for the preparation and presentation of these financial results that give a true and fair view of the net profit and other comprehensive income and other financial information in accordance with the Indian Accounting Standards prescribed under Section 133 of the Act read with relevant rules issued thereunder and other accounting principles generally accepted in India and in compliance with Regulation 33 of the LODR Regulations. This responsibility also includes maintenance of adequate accounting records in accordance with the provisions of the Act for safeguarding of the assets of the Company and for preventing and detecting frauds and other irregularities; selection and application of appropriate accounting policies; making judgments and estimates that are reasonable and prudent; and design, implementation and maintenance of adequate internal financial controls that were operating effectively for ensuring the accuracy and completeness of the accounting records, relevant to the preparation and presentation of the financial results that give a true and fair view and are free from material misstatement, whether due to fraud or error.

LLP IN : AAH - 3437

REGISTERED OFFICE : ESPLANADE HOUSE, 29, HAZARIMAL SOMANI MARG, FORT, MUMBAI 400 001

TEL.: (91) (22) 6158 6200, 6158 7200 FAX : (91) (22) 6158 6275

In preparing the financial results, the Board of Directors are responsible for assessing the Company's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the Board of Directors either intends to liquidate the Company or to cease operations, or has no realistic alternative but to do so.

The Board of Directors are also responsible for overseeing the Company's financial reporting process.

### **Auditor's Responsibilities for the Audit of the Financial Results**

Our objectives are to obtain reasonable assurance about whether the financial results as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance but is not a guarantee that an audit conducted in accordance with SAs will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these financial results.

As part of an audit in accordance with SAs, we exercise professional judgment and maintain professional skepticism throughout the audit. We also:

- Identify and assess the risks of material misstatement of the financial results, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.
- Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances. Under Section 143(3)(i) of the Act, we are also responsible for expressing our opinion on whether the company has adequate internal financial controls with reference to financial statements in place and the operating effectiveness of such controls.
- Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by the Board of Directors.
- Conclude on the appropriateness of the Board of Directors' use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the Company's ability to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the financial results or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause the Company to cease to continue as a going concern.
- Evaluate the overall presentation, structure and content of the financial results, including the disclosures, and whether the financial results represent the underlying transactions and events in a manner that achieves fair presentation.

We communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.

We also provide those charged with governance with a statement that we have complied with relevant ethical requirements regarding independence, and to communicate with them all relationships and other matters that may reasonably be thought to bear on our independence, and where applicable, related safeguards.



## Sanofi Consumer Healthcare India Limited

Registered Office : Unit 1104, 11th Floor, Godrej Two Pirojshanagar, Eastern Express Highway, Vikhroli East, Mumbai, Maharashtra, India, 400079

Corporate Identity Number: U21002MH2023PLC402652

Tel no: (91-22) 45288555

Website: www.sanofi.in Email: igrc.schil@sanofi.com

### STATEMENT OF AUDITED FINANCIAL RESULTS FOR YEAR ENDED DECEMBER 31, 2024

Particulars	₹ in Million				
	Quarter ended 31.12.2024 (Unaudited)  Refer note: 10	Quarter ended 30.09.2024 (Unaudited)	Quarter ended 31.12.2023 (Unaudited)  Refer note: 3 & 10	Year ended 31.12.2024 (Audited)  Refer note: 3	Period ended 31.12.2023 (Audited) wef 10.05.23 - 31.12.2023 Refer note: 3
1. Revenue from Operations	1,707	1,599	2,246	7,245	5,554
2. Other Income	50	42	26	130	41
3. Total Income (1+2)	1,757	1,641	2,272	7,375	5,595
4. Expenses					
(a) Cost of Materials Consumed	148	141	552	1,274	1,364
(b) Purchases of stock in trade	184	144	68	421	200
(c) Changes in Inventories of work-in-progress, stock-in-trade and finished goods	87	102	(11)	166	(45)
(d) Employee benefits expense	276	274	194	1,027	544
(e) Finance costs	4	34	-	39	-
(f) Depreciation and amortisation expense	10	15	7	45	18
(g) Other expenses	391	307	548	1,651	1,303
Total Expenses	1,100	1,017	1,358	4,623	3,384
5. Profit before exceptional items and tax (3-4)	657	624	914	2,752	2,211
6. Exceptional items (Refer notes 6 & 7)	(29)	(12)	(18)	(284)	(18)
7. Profit before tax (5+6)	628	612	896	2,468	2,193
8. Tax expense					
Current Tax	176	169	234	696	563
Deferred Tax	9	(7)	(17)	(38)	(19)
9. Profit for the period /year (7-8)	443	450	679	1,810	1,649
10. Other comprehensive income (OCI)					
Items that will not be reclassified to the statement of profit and loss					
- Remeasurements of post-employment benefit obligations	(19)	-	-	(19)	-
- Income Tax impact relating to these items	5	-	-	5	-
11. Total comprehensive income for the period/year (9+10)	429	450	679	1,796	1,649
12. Paid-up equity share capital (Face Value of ₹ 10 per share)	230	230	20	230	20
13. Share capital pending for allotment (Face Value of ₹ 10 per share)	-	-	230	-	230
14. Other equity	-	-	-	2,500	1,826
15. Basic and diluted earnings per share (not annualised) (in ₹)	19.25	19.52	29.48	78.59	71.60

The statutory auditors have digitally signed this statement for identification purposes only and this Statement should be read in conjunction with our LODR Regulations Audit Report dated February 20, 2025.

**Damarla Sai  
Venkata  
Ramana**

Digitally signed by Damarla Sai Venkata Ramana  
DN: c=IN, o=Person, ou=0721,  
postalCode=53337923946784862999D, email=S.V.  
2.5.4.20-95690185b6251d9702e60151bb8abcf39d61b  
09d6741bb740e934ac62a1063, postalCode=421301,  
st=Telangana  
serialNumber=6085310dd1c0b6fabbb985e6db6cccd3  
e8d17f71e8ccce5c0dd19446b9b121a, cn=Damarla Sai  
Venkata Ramana  
Date: 2025.02.20 19:43:22 +05'30'

**Himanshu  
Bakshi**

Digitally signed by  
Himanshu Bakshi

**Sanofi Consumer Healthcare India Limited**

**STATEMENT OF ASSETS AND LIABILITIES**

₹ in Million

Particulars	As at December 31, 2024 (Audited) Refer note: 3	As at December 31, 2023 (Audited) Refer note: 3
<b>ASSETS</b>		
<b>Non-current assets</b>		
Property, plant and equipment	97	20
Capital work in progress	7	-
Right-of-use assets	175	-
Intangible assets	19	29
Intangible assets under development	-	26
Financial assets		
Other financial assets	36	8
Deferred tax assets (net)	62	19
<b>Total non-current assets</b>	<b>396</b>	<b>102</b>
<b>Current assets</b>		
Inventories	409	966
Financial assets		
(i) Trade receivables	137	316
(ii) Cash and cash equivalents	3,269	16
(iii) Loans	6	5
(iv) Other financial assets	38	2,048
Other current assets	58	1
<b>Total current assets</b>	<b>3,917</b>	<b>3,352</b>
<b>TOTAL ASSETS</b>	<b>4,313</b>	<b>3,454</b>
<b>EQUITY AND LIABILITIES</b>		
<b>Equity</b>		
Equity share capital	230	20
Share pending issuance	-	230
<b>Other equity</b>		
Reserves and Surplus	2,500	1,826
<b>Total equity</b>	<b>2,730</b>	<b>2,076</b>
<b>LIABILITIES</b>		
<b>Non-current liabilities</b>		
Financial liabilities		
Lease liabilities	166	-
Employee benefit obligations	111	79
<b>Total non-current liabilities</b>	<b>277</b>	<b>79</b>
<b>Current liabilities</b>		
Financial liabilities		
(i) Lease liabilities	37	-
(ii) Trade payables		
(a) Total outstanding dues of micro enterprises and small enterprises	33	76
(b) Total outstanding dues of creditors other than micro enterprises and small enterprises	670	524
Employee Benefit Obligations	244	129
Other current liabilities	141	-
Provisions	178	49
Current tax liabilities (net)	3	521
<b>Total current liabilities</b>	<b>1,306</b>	<b>1,299</b>
<b>Total current liabilities</b>	<b>1,583</b>	<b>1,378</b>
<b>TOTAL EQUITY AND LIABILITIES</b>	<b>4,313</b>	<b>3,454</b>

The statutory auditors have digitally signed this statement for identification purposes only and this Statement should be read in conjunction with our LODR Regulations Audit Report dated February 20, 2025.

**Damarla Sai Venkata Ramana**

Digitally signed by Damarla Sai Venkata Ramana  
DN: c=IN, o=Personal, ou=0721,  
pseudonym=133317923944578480c299PPOJ51915V,  
2.5.4.20=956901f85b6251d9702e60151b8fabcf9d61b09de7  
41bb740d934acf2a1063, postalCode=421301,  
st=Maharashtra,  
serialNumber=6085310dd1d0b64abb985e6d0c4ced3e8d17  
f71e8cccf5c0dd19446b9b121a, cn=Damarla Sai Venkata  
Ramana  
Date: 2025.02.20 19:44:01 +05'30'

**Himanshu Bakshi**

Digitally signed  
by Himanshu  
Bakshi

**Sanofi Consumer Healthcare India Limited**

**STATEMENT OF CASH FLOWS FOR THE YEAR ENDED DECEMBER 31, 2024**

₹ in Million

Particulars	Year ended December 31, 2024 Audited	Year ended December 31, 2023 Audited
<b>Cash flows from Operating activities</b>	<b>2,468</b>	<b>2,193</b>
<b>Profit before tax</b>		
<b>Adjustment for :</b>		
Depreciation and amortization expenses	45	18
Unrealised exchange (gain)	(1)	-
Finance costs	39	-
Interest income	(118)	(40)
Share based payment	10	-
Provision for bad and doubtful debts (net)	1	-
Impairment on Intangible Asset Under development classified under exceptional item	29	-
<b>Operating profit before working capital changes</b>	<b>2,473</b>	<b>2,171</b>
<b>Adjustments for (increase) / decrease in operating assets</b>		
Non-current financial assets	(28)	-
Inventories	557	(42)
Trade receivables	179	(3)
Current financial assets	2,010	(2,053)
Loans	(1)	-
Other current assets	(57)	(1)
<b>Adjustments for increase / (decrease) in operating liabilities</b>		
Employee benefit obligations	128	(41)
Trade payables	103	116
Other current liabilities & provisions	270	(109)
<b>Cash generated from operations</b>	<b>5,634</b>	<b>38</b>
Taxes paid (net of refunds)	(1,244)	(42)
<b>Net Cash inflow / (outflow) from Operating activities (A)</b>	<b>4,390</b>	<b>(4)</b>
<b>Cash flows from Investing activities</b>		
Interest received	118	40
Purchase of property, plant and equipment and Intangible assets including Capital work-in-progress	(99)	(40)
<b>Net cash inflow from Investing activities (B)</b>	<b>19</b>	<b>-</b>
<b>Cash flows from financing activities</b>		
Issue of Share Capital	-	20
Interest paid on lease	(4)	-
Dividend paid (Refer note 3 and 4)	(1,152)	-
<b>Net cash used in financing activities (C)</b>	<b>(1,156)</b>	<b>20</b>
<b>Net increase in cash and cash equivalents (A+B+C)</b>	<b>3,253</b>	<b>16</b>
Cash and Cash Equivalents at the beginning of the year/period	16	-
<b>Cash and Cash Equivalents at the end of the year/period</b>	<b>3,269</b>	<b>16</b>
<b>Non- cash financing and investing activities (D)</b>		
Acquisition of Right-of-use assets	198	
<b>Components of Cash and Cash Equivalents</b>		
<b>Cash and Cash Equivalents at the end of the year/period</b>	<b>3,269</b>	<b>16</b>

The statutory auditors have digitally signed this statement for identification purposes only and this Statement should be read in conjunction with our LODR Regulations Audit Report dated February 20, 2025.

Damarla Sai  
Venkata Ramana

Digitally signed by Damarla Sai Venkata Ramana  
DN: c=IN, o=Personal, title=0721,  
pseudonym=133317923944578480x29PPDz5b915V,  
2.5.4.20-956901f85b6251d9702e60151b8fab39d61b09de741bb7  
40d934cfcf2a1063, postalCode=421301, st=Maharashtra,  
serialNumber=5085310d81d0b64abbd985e60c4ced3e8d17f71e8c  
cfc5c0dd19446b9b121a, cn=Damarla Sai Venkata Ramana  
Date: 2025.02.20 19:45:06 +05'30'

Himanshu Bakshi  
Digitally signed  
by Himanshu  
Bakshi

**Notes:**

1. These audited financial results have been prepared in accordance with recognition and measurement principles of the Indian Accounting Standards ("Ind AS"), as prescribed under section 133 of the Companies Act, 2013, read with relevant rules issued thereunder and the other accounting principles generally accepted in India.
2. The statutory auditors have issued audit report with unmodified conclusion on the above audited financial results for the quarter and year ended December 31, 2024. The audited financial results which are published in accordance with Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 have been reviewed by the Audit Committee in their meeting held on February 20, 2025, and approved by the Board of Directors of the Company at its meeting held on February 20, 2025.
3. The Board of Sanofi India Limited (SIL) on May 10, 2023, had approved a Scheme of Arrangement under Sections 230 to 232 of the Companies Act, 2013 ("Scheme"), to demerge the Consumer Healthcare business of Sanofi India Limited into its wholly owned subsidiary Sanofi Consumer Healthcare India Limited ("SCHIL"). In accordance with the Scheme of Arrangement between Sanofi India Limited and its shareholders and creditors and SCHIL ("the Scheme") as approved by the Hon'ble National Company Law Tribunal, Mumbai Bench by an order dated May 7, 2024, the Consumer Healthcare Business, along with its related assets and liabilities at the values appearing in the books of accounts of SIL on the close of business hours as on May 10, 2023 (Incorporation Date), was demerged, transferred and vested into the Company with effect from May 10, 2023 as set out in Appendix C of Ind AS 103 'Business Combinations'. The appointed date and effective date of the Scheme was June 1, 2023 and June 1, 2024 respectively, however, financials are drawn from May 10, 2023 as per the requirement of Ind AS 103. Business was run by SIL in trust for SCHIL and risk associated with the business remains with SCHIL from date of business transfer. Accordingly, the previous year results and results for the year ended December 2023 are from May 10, 2023, to December 31, 2023, and not comparable with current year quarter and the year ended December 2024.
4. Pursuant to the demerger, the Company has recognized in its books of account, the carrying amount of assets and liabilities as on May 31, 2024, pertaining to the Consumer Healthcare business transferred from SIL. The excess of the carrying amount of assets transferred over the carrying amount of liabilities transferred and profit earned from May 10, 2023 to May 31, 2024 aggregating to ₹ 1,902 million (including capital reserve of ₹407 million) and net of dividend paid by SIL in trust on behalf of the Company amounting to ₹ 1,152 million has been credited to reserves in accordance with the Scheme as on May 31, 2024.
5. The record date, for determining the eligibility of the shareholders of SIL for allotting shares of the SCHIL in the ratio of 1 (One) fully paid-up new equity share of ₹ 10 each of the Company for every 1 (One) equity share of ₹ 10 each of SIL (pursuant to the Scheme of Arrangement) was fixed as June 13, 2024. Accordingly, the Company has allotted 23,030,622 shares amounting to ₹ 230 million (adjusted against Capital Reserve) to the eligible shareholders of SIL on June 25, 2024.
6. Company had voluntarily decided to recall Allegra Suspension and Combiflam Suspension as precautionary measure from distributors, hospitals, and retailers on July 19, 2024. Earlier, Company recalled Depura Adult and Depura Kids produced by the same manufacturer. The recall of the products is substantially completed from distributors and it is expected to receive minor returns from retailers by June 2025. The Company has taken a decision to temporarily suspend manufacturing of aforesaid products to review and streamline the manufacturing and quality processes at the third-party manufacturer engaged in manufacturing. Quality is paramount to the Company and the endeavor is to bring back the products to the market as soon as possible. Our non-recalled portfolio continues to perform strongly in the market.
7. Exceptional items for the year ended December 31, 2024, amounts to ₹ 284 million which includes product recall related cost towards Sales return and inventory write off ₹ 108 million, expenses towards listing formalities amounting to ₹ 77 million, demerger expenses amounting to ₹ 70 million and Intangible asset under development written off amounting to ₹ 29 million, which was acquired under the Scheme of Arrangement (Refer Note :3) based on the internal assessment done by the company of its recoverability. (Previous period ended December 31, 2023: ₹ 18 million which is towards demerger expenses).
8. The Board has recommended a final dividend of ₹ 55 per equity share of ₹ 10 for the year ended December 31, 2024, which would be paid after approval of shareholders at the ensuing Annual General Meeting of the Company.
9. The Company has a single business segment namely 'Pharmaceutical Business'.

10. The figures for the quarter ended December 31, 2024 and December 31, 2023 are the balancing figures between audited figures in respect of the full financial year up to December 31, 2024 and December 31, 2023 and the unaudited published year-to-date figures up to September 30, 2024 and September 30, 2023 respectively, which were subject to a limited review, being the date of the end of the third quarter of the said financial year.
11. The Company listed its equity shares with the National Stock Exchange of India Limited (“NSE”) and the BSE Limited (“BSE”) on September 13, 2024.
12. There is a change of Holding Company from ‘Hoechst GmbH and Sanofi S.A. to ‘Opella Healthcare Participations BV’ in October 2024. However, Sanofi S.A remains the ultimate Holding Company.
13. The Company does not have any subsidiary, associates or joint ventures as on December 31, 2024.

The statutory auditors have digitally signed this statement for identification purposes only and this Statement should be read in conjunction with our LODR Regulations Audit Report dated February 20, 2025.

**Damarla Sai  
Venkata Ramana**

Digitally signed by Damarla Sai Venkata Ramana  
DN: cn=#, ou=Personnel, email=0721,  
pseudonym=133317923944578450x29PPDzj5b915V,  
2.5.4.20=956901f85b6251d9702e60151b8fabcf39d61b09d6741  
bb7409934acfd2a1062, postalCode=421301, st=Maharashtra,  
serialNumber=6095319d4c1d0b-fabbd089d0b4cc35e0d17f  
Te8cccf5c0dd19446b9b121a, cn=Damarla Sai Venkata Ramana  
Date: 2025.02.20 19:45:47 +05'30'

**SANOFI CONSUMER HEALTHCARE INDIA LIMITED**

**Himanshu  
Bakshi**

Digitally signed by  
Himanshu Bakshi

**Himanshu Bakshi**  
Managing Director  
DIN: 08188412

**February 20, 2025**

Related party transactions										Additional disclosure of related party transactions - applicable only in case the related party transaction relates to loans, other corporate deposits, advances or investments made or given by the listed entity/ subsidiary. These details need to be disclosed only once during the reporting period when such transaction was undertaken.													
Sl. No.	Details of the party (listed entity/ subsidiary) entering into the transaction		Details of the counterparty		Relationship of the counterparty with the listed entity or its subsidiary	Type of related party transaction	Details of other related party transaction	Value of the related party transaction as approved by the audit committee	Remarks on approval by audit committee	Value of transaction during the reporting period	In case monies are due to/other party as a result of the transaction		In case any financial relationships are entered into with the party, other corporate deposits, advances or investments				Details of the loans, other corporate deposits, advances or investments				Particular for which the funds will be utilized by the ultimate recipient of funds (wherever)	Notes	
	Name	PAN	Name	PAN							Opening balance	Closing balance	Balance of individuals (loan/ advance/ any other etc.)	Details of other individuals	Cost	Tenure	Interest Rate (%)	Tenure	Secured/ unsecured				
Add	Debit																						
1	SANGHI CONSUMER HEALTHCARE INDIA LIMITED	AB0279120	SANGHI INDIA LIMITED	AAACH278F	Common control	Purchase of goods or services			227.00	No Remark	228.51	0.00	0.00										
2	SANGHI CONSUMER HEALTHCARE INDIA LIMITED	AB0279120	SANGHI INDIA LIMITED	AAACH278F	Common control	Interest received			9.72	No Remark	9.20	0.00	0.00										
3	SANGHI CONSUMER HEALTHCARE INDIA LIMITED	AB0279120	SANGHI INDIA LIMITED	AAACH278F	Common control	Consignment Agency			202.00	No Remark	1.84	0.00	0.00										
4	SANGHI CONSUMER HEALTHCARE INDIA LIMITED	AB0279120	SANGHI INDIA LIMITED	AAACH278F	Common control	Any other transaction	Other expenses		5.00	No Remark	3.50	0.00	0.00										
5	SANGHI CONSUMER HEALTHCARE INDIA LIMITED	AB0279120	SANGHI INDIA LIMITED	AAACH278F	Common control	Any other transaction	Bank Paid		20.00	No Remark	25.62	0.00	0.00										
6	SANGHI CONSUMER HEALTHCARE INDIA LIMITED	AB0279120	SANGHI INDIA LIMITED	AAACH278F	Common control	Any other transaction	Expense Not Incurred		20.24	No Remark	16.70	0.00	0.00										
7	SANGHI CONSUMER HEALTHCARE INDIA LIMITED	AB0279120	SANGHI INDIA LIMITED	AAACH278F	Common control	Any other transaction	Expense Recharge		17.00	No Remark	17.15	0.00	0.00										
8	SANGHI CONSUMER HEALTHCARE INDIA LIMITED	AB0279120	SANGHI INDIA LIMITED	AAACH278F	Common control	Any other transaction	Inventory Transfer (Cost)		217.80	No Remark	237.30	0.00	0.00										
9	SANGHI CONSUMER HEALTHCARE INDIA LIMITED	AB0279120	SANGHI HEALTHCARE INDIA PRIVATE LIMITED	AA025682G	Common control	Any other transaction	Insurance Agent		10.00	No Remark	1.40	0.00	0.00										
10	SANGHI CONSUMER HEALTHCARE INDIA LIMITED	AB0279120	SANGHI HEALTHCARE INDIA PRIVATE LIMITED	AA025682G	Common control	Any other transaction	Service Charges received		100.00	No Remark	147.50	0.00	0.00										
11	SANGHI CONSUMER HEALTHCARE INDIA LIMITED	AB0279120	SANGHI HEALTHCARE INDIA PRIVATE LIMITED	AA025682G	Common control	Any other transaction	Service Charges received (Income)		121.00	No Remark	124.87	0.00	0.00										
12	SANGHI CONSUMER HEALTHCARE INDIA LIMITED	AB0279120	INTERNATIONAL LAS	AA020170C	Common control	Any other transaction	Tab of goods or services		80.00	No Remark	46.24	0.00	0.00										
13	SANGHI CONSUMER HEALTHCARE INDIA LIMITED	AB0279120	HEMANSHU BASHI	AG0F8019D	Any management personnel of	Any other transaction	Remuneration		18.21	No Remark	18.21	0.00	0.00										
14	SANGHI CONSUMER HEALTHCARE INDIA LIMITED	AB0279120	SURENDRAKUMAR AGARWAL	AA0F4788A	Any management personnel of	Any other transaction	Remuneration		7.20	No Remark	7.20	0.00	0.00										
15	SANGHI CONSUMER HEALTHCARE INDIA LIMITED	AB0279120	NAKUL SAVALYA	BB0F9789N	Any management personnel of	Any other transaction	Remuneration		5.62	No Remark	5.62	0.00	0.00										
16	SANGHI CONSUMER HEALTHCARE INDIA LIMITED	AB0279120	HEMANSHU BASHI	AG0F8019D	Any management personnel of	Any other transaction	FGDP		1.81	No Remark	1.81	0.00	0.00										
17	SANGHI CONSUMER HEALTHCARE INDIA LIMITED	AB0279120	SURENDRAKUMAR AGARWAL	AA0F4788A	Any management personnel of	Any other transaction	FGDP		1.10	No Remark	1.10	0.00	0.00										
18	SANGHI CONSUMER HEALTHCARE INDIA LIMITED	AB0279120	AMIT JAIN	AA0F8366K	Any management personnel of	Any other transaction	FGDP		1.00	No Remark	1.00	0.00	0.00										
19	SANGHI CONSUMER HEALTHCARE INDIA LIMITED	AB0279120	SUBHINDER DUGGAL	AA0D0376B	Any management personnel of	Any other transaction	FGDP		1.00	No Remark	1.00	0.00	0.00										
20	SANGHI CONSUMER HEALTHCARE INDIA LIMITED	AB0279120	SUPARNA PANDHAR	AA0P0213A	Any management personnel of	Any other transaction	FGDP		1.00	No Remark	1.00	0.00	0.00										
21	SANGHI CONSUMER HEALTHCARE INDIA LIMITED	AB0279120	HOECHST-CHEMIE GERMANY	AAACH2007P	Ultimate Holding Company	Dividend paid			691.00	No Remark	696.00	0.00	0.00										
22	SANGHI CONSUMER HEALTHCARE INDIA LIMITED	AB0279120	SANGHI INDIA LIMITED	AAACH278F	Common control	Any other transaction	Inventory Transfer (Cost)		0.00	No Remark	67.41	0.00	0.00										
23	SANGHI CONSUMER HEALTHCARE INDIA LIMITED	AB0279120	INTERNATIONAL LAS	AA020170C	Common control	Any other transaction	Closing Balance		0.00	No Remark	0.00	0.00	28.00										
24	SANGHI CONSUMER HEALTHCARE INDIA LIMITED	AB0279120	SANGHI INDIA LIMITED	AAACH278F	Common control	Any other transaction	Closing Balance		0.00	No Remark	0.00	0.00	63.00										
25	SANGHI CONSUMER HEALTHCARE INDIA LIMITED	AB0279120	SANGHI HEALTHCARE INDIA PRIVATE LIMITED	AAACH278F	Common control	Any other transaction	Closing Balance		0.00	No Remark	0.00	0.00	35.00										
26	SANGHI CONSUMER HEALTHCARE INDIA LIMITED	AB0279120	SANGHI INDIA LIMITED	AAACH278F	Common control	Any other transaction	Closing Balance		0.00	No Remark	0.00	0.00	288.00										

Total value of transactions during the reporting period

INR 6.48 Lakhs